clinical trial · NCT06875310
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.·phase3·recruiting·n = 630
Carcinoma, Non-Small-Cell LungAdagrasibPembrolizumabCarboplatinPemetrexedPlaceboCisplatin
brief summary
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
started
Apr 24, 2025
primary completion
Sep 7, 2029
completion
Apr 30, 2032
last updated
Apr 7, 2026
official title
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol